FOLH1 and Familial prostate cancer: In future studies, clinical sample staining will be evaluated to assess the diagnostic accuracy of the DDSI methodology in mixed, heterogeneous samples, and additional biomarkers will be evaluated for low PSMA expressing prostate cancers.